Search Videos and More
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood CancerA new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
Study Unravels a Cause of Resistance to Novel Drug in Patients with Acute LeukemiaA new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
Season 2, Episode 2: Thalidomide and its Second Act in Multiple MyelomaMomentum isn't always one way. And it's not always constant. Sometimes it shoves you sideways, sometimes it stops you in your tracks. And sometimes only sometimes, it drives you to write one of the most astonishing second acts in all of medicine. That's the story of thalidomide.
Smoldering Multiple Myeloma - A Unique New ApproachWhen Deidre was diagnosed with a precursor condition to multiple myeloma she enrolled in a brand-new clinical trial being conducted at Dana-Farber Cancer Institute. Deidre and her doctor, Dana-Farber's Irene Ghobrial, MD, explain more in this video.
Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic LeukemiaOn Thursday, January 19, 2023, the FDA approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of FrailtyA new tool developed by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital outperforms conventional methods for predicting whether certain medications are likely to lead to frailty in older patients with blood cancers who are taking multiple medications, a study being published online today indicates.
In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology ProgramThe Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaInhye Ahn, MD, discusses the background and management of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Hodgkin LymphomaAnn LaCasce, MD, MMSc, discusses Hodgkin lymphoma and how to approach the different types of Hodgkin patients.
CAR-T Cell Therapy for Lymphoma: Updates and ProgressCaron Jacobson, MD, MMSc, gives updates and shares progress with CAR-T cell therapy for lymphoma.
Hematologic Malignancies CME: 2021The care of patients with hematologic malignancies is evolving rapidly. These video highlights discuss new developments in the diagnosis and treatment of hematologic malignancies presented at the 2021 Annual Meeting of the American Society of Hematology (ASH).
Blood Cancer Research: Clinical Trial Helps Younger PatientA patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.